Sector News

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

July 22, 2019
Life sciences

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more.

This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US mRNA biotech Moderna last year. It’s also to be expected, coming from the company that developed the blockbuster blood cancer drug Darzalex in partnership with Janssen.

Genmab will use the money to push the development of its antibody drugs. The company has two antibodies in phase III, one being developed with Novartis for the treatment of the neurological disease multiple sclerosis, and the other with Horizon Pharma for the treatment of thyroid-related eye disease. Genmab has many other partnered and proprietary programs ongoing, including developing a preclinical drug with Janssen with the potential to outperform Darzalex in some tumor types.

With a market cap of over €10B ($11B), Genmab’s position as Europe’s most valuable biotech is secure for the time being. The company has proved popular with investors since the beginning, with a record IPO of €210M on the Copenhagen Stock Exchange back in 2000, just a year after it was founded.

By: Jonathan Smith

Source: Labiotech.eu

2 responses to “Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend